The drug developer raised nearly $330m earlier this year according to its IPO filing, with $110m being supplied by SoftBank Vision Fund.

Telecommunications group SoftBank’s Vision Fund will get the chance to exit US-based infectious disease therapy developer Vir Biotechnology after the latter filed for a $100m initial public offering on Tuesday. Vir is working on treatments for infectious diseases, having created four drug development platforms covering T cells, antibodies, innate immunity and small interfering ribonucleic acid…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.